New HELIOS-B data show reduced gastrointestinal events with vutrisiran

Alnylam Pharmaceuticals has released new post hoc results from its HELIOS-B Phase 3 study, reporting lower rates of gastrointestinal (GI) adverse events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with vutrisiran, compared to placebo. According to the company, in the overall study population, treatment with vutrisiran was associated with a 42 % lower rate […] The post New HELIOS-B data show reduced gastrointestinal events with vutrisiran appeared first on Longevity.Technology.